Novartis evaluating options for generics and biosimilars unit

Early-stage approaches aim for more precise immune suppression, remyelination

Pharma fails to present persuasive case on drug pricing

The House Committee on Oversight and Reform Wednesday released reports and documents that, according to committee Democrats, demonstrate that drug companies take unjustified price increases and engage

The introduction of generic competition in the U.S. for MS blockbuster Tecfidera, which accounted for 40% of Biogen’s product revenue last half, puts increased pressure on the remainder of big

Myasthenia gravis POC readout closely preceded pharma’s premium bid

Why neurofilaments could become the go-to biomarker for neurodegeneration